Rosetta Lifecare signed with Enzolytics Inc. agreement on exclusive distribution rights for the distribution of their ITV1 product for the treatment of HIV / AIDS and Hepatitis C for the following countries: Pakistan, United Arab Emirates, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda Northern Sudan, Egypt, Morocco and Tunisia. The drug is in an inspection form based on the IPF platform and has shown very good results in clinical trials.
So these are the countries ENZC is going to start curing HIV/AIDS? This isn`t the immune booster from Enzoimmune Active.
News 
Market Data 
Discover 
AI
